The Ramsay Health Care (ASX:RHC) share price has tumbled 7% this month. Is it a buy?

Is now the time to buy Ramsay shares?

| More on:
A male Avita Medical doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused

Image source: Getty Images

The Ramsay Health Care Limited (ASX: RHC) share price has been underperforming in 2021.

Since the start of the year, the private hospital operator’s shares have risen just 5.5%. This follows a 7% decline so far in November.

Is the Ramsay share price good value now?

The subdued performance of the Ramsay share price this year has been driven by concerns over the difficult trading conditions the company is facing in Australia from lockdowns.

The good news, though, is that the team at Goldman Sachs believe this underperformance is a buying opportunity for investors.

According to a recent note, the broker has reiterated its buy rating and $74.00 price target on its shares.

Based on the current Ramsay share price of $66.20, this implies potential upside of approximately 12% for investors over the next 12 months.

Goldman is also forecasting a dividend yield of approximately 2% in FY 2022, bringing the total return on offer to ~14%.

Why does Goldman like Ramsay?

Goldman continues to highlight Ramsay as one of the more attractive recovery trades across its coverage.

It commented: “RHC’s operating performance in 1Q22 was heavily impacted by various restrictions, lockdowns and other challenges associated with the pandemic. However: 1) these dynamics were widely understood (and experienced by most) prior to today; and 2) positive revenue growth (+1.3%) was ahead of our expectations given the severity of disruption during the period (widespread elective surgery bans/restrictions, isolation orders/lockdowns and infection-driven staffing shortages/procedure cancellations).”

“Despite these challenges, growth was positive in each of UK (+21%), Europe (+5%) and Asia (+15%), as the extent of volume recovery more than offset the impact of Covid-driven disruption and, whilst operating performance remains some way below pre-Covid levels, an improving trajectory is clear, and we believe the set-up for 2022 looks favourable,” the broker added.

All in all, Goldman Sachs appears to believe it could be worth sticking with the Ramsay share price and sees strong returns on the horizon.

Should you invest $1,000 in Ramsay right now?

Before you consider Ramsay, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Ramsay wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes